Habib George, Khazin Fadi, Sakas Fahed, Hakim Geries, Artul Suheil
Rheumatology Unit, Laniado Hospital, Netanya, Israel.
Rheumatology Clinic, Nazareth Hospital, Israel Institute of Technology School of Medicine, Haifa, Israel.
Eur J Rheumatol. 2018 Jul;5(2):96-99. doi: 10.5152/eurjrheum.2018.17133. Epub 2018 Feb 13.
To evaluate the effect of intra-articular (IA) corticosteroid injection (IACI) of betamethasone dipropionate/betamethasone sodium phosphate (Diprospan) on blood glucose levels in diabetic patients METHODS: Patients with type 2 diabetes and symptomatic osteoarthritis of the knee (OAK) in whom medical therapy failed were administered 1 mL Diprospan IACI (5 mg of betamethasone dipropionate +2 mg of betamethasone sodium phosphate). Patients were asked to monitor blood glucose levels before and 2 h after meals for 1 week before and 12 days after the injection was administered. A control group was administered an IA injection of hyaluronic acid.
Twelve patients from the Diprospan group and six from the control group were recruited for the study. Patients in the Diprospan group had significantly increased blood glucose levels with median initial and peak levels of 187.5 mg% and 310 mg%, respectively, at a median of 4 and 11.5 h following IACI, respectively. The last peak level was seen after a median of 45 h following IACI. There was no significant increase in blood glucose levels in the control group.
Diprospan IACI is associated with significantly increased blood glucose levels in all diabetic patients with OAK.
评估关节内注射二丙酸倍他米松/倍他米松磷酸钠（得宝松）对糖尿病患者血糖水平的影响。方法：对2型糖尿病且膝关节症状性骨关节炎（OAK）经药物治疗无效的患者，给予1 mL得宝松关节内注射（含5 mg二丙酸倍他米松 + 2 mg倍他米松磷酸钠）。要求患者在注射前1周及注射后12天，监测餐前及餐后2小时的血糖水平。对照组给予关节内注射透明质酸。结果：得宝松组招募了12例患者，对照组招募了6例患者。得宝松组患者血糖水平显著升高，关节内注射后，中位初始血糖水平和峰值水平分别为187.5 mg%和310 mg%，分别出现在注射后的中位4小时和11.5小时。最后一个峰值水平出现在关节内注射后的中位45小时。对照组血糖水平无显著升高。结论：得宝松关节内注射与所有患OAK的糖尿病患者血糖水平显著升高有关。
